Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pegozafermin by 89Bio for Fibrosis: Likelihood of Approval
Pegozafermin is under clinical development by 89Bio and currently in Phase III for Fibrosis. According to GlobalData, Phase III drugs...
Pegozafermin by 89Bio for Liver Cirrhosis: Likelihood of Approval
Pegozafermin is under clinical development by 89Bio and currently in Phase III for Liver Cirrhosis. According to GlobalData, Phase III...
Pegozafermin by 89Bio for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pegozafermin is under clinical development by 89Bio and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of 89bio's Pegozafermin?
Pegozafermin is a recombinant protein commercialized by 89bio, with a leading Phase III program in Fibrosis. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of 89bio's Pegozafermin?
Pegozafermin is a recombinant protein commercialized by 89bio, with a leading Phase III program in Hypertriglyceridemia. According to Globaldata, it...